Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
No wonder early commentators have lauded triple-agonists as a potential home run for obesity treatment
Thyroid cancer history As discussed, cagrilintide is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or MEN2
Rybelsus, an oral version of semaglutide, was initially designed for type 2 diabetes but has shown promise for weight loss, particularly in clinical trials
Optimization of a glucagon-like peptide 1 receptor antagonist antibody for treatment of hyperinsulinism
Enhances Insulin Sensitivity: GLP-1 improves insulin sensitivity, particularly in muscle tissue, allowing cells to utilize glucose more efficiently for energy rather than storing it as fat
US$ 25.79
US$ 29.57
US$ 24.96
US$ 24.00
US$ 20.56
